US2006141550A1PendingUtilityA1

Novel metabolic targets and markers

43
Individually held — no corporate assignee on recordPriority: Mar 11, 2002Filed: Nov 30, 2005Published: Jun 29, 2006
Est. expiryMar 11, 2022(expired)· nominal 20-yr term from priority
Inventors:Steven M. WatkinsRebecca A. Baillie
A61P 9/00A61K 31/455A61K 31/519A61K 31/7076C12Y 201/01017A61K 38/27A61K 31/00G01N 2800/52G01N 33/92C12N 9/1003A61K 31/51A61K 31/4415A61P 25/00G01N 33/5758
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides metabolic markers and targets, especially PEMT activity and metabolic markers and components associated therewith useful for diagnosing and treating various disease conditions.

Claims

exact text as granted — not AI-modified
1 . A method for regulating the level of a fatty acid in a system comprising regulating the phosphatidylethanolamine-N-methyltransferase (PEMT) activity in the system whereby regulating the level of a fatty acid in the system, wherein the fatty acid is selected from the group consisting of 16:0, 18:0, 16:1n7, 18:1n7, 18:2n6, 20:4n6, 20:5n3, 22:6n3, saturated fatty acids, polyunsaturated fatty acids, and highly unsaturated fatty acids.  
   
   
       2 . The method of  claim 1 , wherein the level of the fatty acid is increased by increasing the PEMT activity and wherein the fatty acid is selected from the group consisting of 18:0, 18:1n7, 20:4n6, 20:5n3, 22:6n3, polyunsaturated fatty acids, and highly unsaturated fatty acids.  
   
   
       3 . The method of  claim 1 , wherein the level of the fatty acid is increased by increasing the PEMT activity relative to CDP-choline activity and wherein the fatty acid is selected from the group consisting of 18:0, 18:1n7, 20:4n6, 20:5n3, 22:6n3, polyunsaturated fatty acids, and highly unsaturated fatty acids.  
   
   
       4 . The method of  claim 1 , wherein the level of the fatty acid is increased by decreasing the PEMT activity and wherein the fatty acid is selected from the group consisting of 16:0, 16:1n7, 18:2n6, and saturated fatty acids.  
   
   
       5 . The method of  claim 1 , wherein the level of the fatty acid is increased by decreasing the PEMT activity relative to CDP-choline activity and wherein the fatty acid is selected from the group consisting of 16:0, 16:1n7, 18:2n6, and saturated fatty acids.  
   
   
       6 . The method of  claim 1 , wherein the fatty acid is in plasma.  
   
   
       7 . The method of  claim 1 , wherein the fatty acid is in a tissue.  
   
   
       8 . The method of  claim 1 , wherein the fatty acid is in milk.  
   
   
       9 . The method of  claim 1 , wherein the fatty acid is in a lipid class.  
   
   
       10 . The method of  claim 1 , wherein the fatty acid is in phosphatidylcholine or cholesterol esters.  
   
   
       11 . A method for decreasing the level of a fatty acid in a system comprising decreasing the CDP-choline activity in the system whereby decreasing the level of a fatty acid in the system, wherein the fatty acid is selected from the group consisting of 16:0, 16:1n7, 18:2n6, and saturated fatty acids.  
   
   
       12 . The method of  claim 11 , wherein the fatty acid is in plasma.  
   
   
       13 . The method of  claim 11 , wherein the fatty acid is in a tissue.  
   
   
       14 . The method of  claim 11 , wherein the fatty acid is in milk.  
   
   
       15 - 16 . (canceled)  
   
   
       17 . A method for regulating a lipoprotein component ratio in a system comprising regulating the PEMT activity in the system whereby regulating the lipoprotein component ratio in the system, wherein the lipoprotein component ratio is selected from the group consisting of cholesterol ester to phosphatidylcholine, cholesterol ester to apoprotein, free cholesterol to apoprotein, and triacylglyceride to phosphatidylcholine.  
   
   
       18 . The method of  claim 17 , wherein the lipoprotein component ratio is in plasma.  
   
   
       19 . The method of  claim 17 , wherein the lipoprotein component ratio is in a lipoprotein.  
   
   
       20 . The method of  claim 17 , wherein the lipoprotein component ratio is in a lipoprotein selected from the group consisting of LDL, VLDL, HDL, IDL, chylomicron remnants, HDL subclasses, and chylomicron.  
   
   
       21 . The method of  claim 17 , wherein the PEMT activity is relative to the CDP-choline activity.  
   
   
       22 . The method of  claim 17 , wherein the PEMT activity is in liver, intestine, heart, brain, or mammary tissue.  
   
   
       23 - 156 . (canceled)

Join the waitlist — get patent alerts

Track US2006141550A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.